Last updated: June 8, 2026
CATAPRES-TTS-1 (clonidine hydrochloride transdermal system, 1.0 mg/24 hours) is supplied in the US under the brand by Bausch Health US, LLC (formerly Salix/Actavis legacy structures in the US portfolio). Distribution into the channel runs through standard wholesale distribution networks tied to the brand’s US manufacturing and supply chain.
Who supplies CATAPRES-TTS-1 to US wholesalers and pharmacies?
Answer: The brand is supplied under Bausch Health US, LLC, distributed through national pharmaceutical wholesalers and contracted distribution partners used by retail pharmacies, health systems, and government formularies.
Which entities are typically upstream of Bausch Health for CATAPRES-TTS-1?
CATAPRES-TTS-1 is a transdermal drug product. Upstream supply generally breaks into three layers:
- Drug product holder / NDA holder (brand sponsor responsible for label, regulatory filings, and commercial supply)
- Commercial manufacturing site(s) (site that produces finished dosage forms and releases lots)
- Packaging and component suppliers (backing film, adhesive layers, release liners, and transdermal component systems)
For CATAPRES-TTS-1, the commercial “supplier” that matters for procurement and contracting is the brand sponsor (Bausch Health US, LLC). The operational upstream manufacturers and component suppliers are not consistently disclosed in public-facing supplier lists the way they are for some biologics and device products.
What do hospital formularies and GPO ordering typically identify?
Hospital and pharmacy ordering systems usually key on:
- Brand name
- NDC
- Labeler (as shown on the NDC directory)
- Wholesaler fulfillment
For branded transdermals, the labeler on the NDC is the primary procurement “supplier” reference for contracting and purchasing.
What is the NDC labeler and how does it map to suppliers for CATAPRES-TTS-1?
Answer: Use the NDC directory labeler as the authoritative “supplier” identity for procurement. For branded CATAPRES-TTS-1, the labeler corresponds to the US brand sponsor.
How to interpret NDC labeler in supplier terms
In the NDC directory:
- Labeler is the entity responsible for the drug product label
- Manufacturer can denote the manufacturing or release activity
- Distributor is often the channel fulfillment partner through wholesalers
For branded products, labeler-to-supplier mapping is the most actionable procurement linkage.
What contract manufacturing sites supply the transdermal dosage form for CATAPRES-TTS-1?
Answer: CATAPRES-TTS-1 uses finished-form transdermal manufacturing and lot release under the brand’s regulated quality system. The contract manufacturing and packaging site names are not reliably available in supplier lists without relying on private procurement documents or product-specific regulatory chemistry/manufacturing disclosures.
What supplier categories exist for transdermal systems?
Transdermal systems typically require:
- Active drug substance handling and controlled-release design
- Adhesive layer manufacturing
- Laminated backing/release liner assembly
- Sterile-free assembly (transdermals are not typically sterile, but must meet microbial and quality requirements)
- Line clearance, in-process controls, and finished-goods testing
- Packaging configuration validation (pouches, cartons, and labeling)
Which wholesalers distribute CATAPRES-TTS-1 and how do you source it quickly?
Answer: CATAPRES-TTS-1 is distributed through standard US pharmaceutical wholesaler networks. Procurement teams typically source via their contracted distributor (the same systems used for most chronic-care branded drugs).
Common distributor channels used for branded transdermals
Most hospitals and retail chains fulfill from:
- National wholesalers with GPO integration
- Secondary distributors for specialty handling, if needed
- Direct fulfillment models where the brand sponsor or distributor offers contracted logistics
Procurement readiness depends on NDC visibility and contract coverage, not on alternative “multiple suppliers” at the active-product level.
Are there multiple CATAPRES-TTS-1 suppliers or only one labeler?
Answer: Branded CATAPRES-TTS-1 is supplied by a single labeled brand sponsor in the US, though logistics can involve multiple wholesalers and fulfillment partners.
What “multiple suppliers” usually means in branded transdermals
- One labeler/brand sponsor for the finished product
- Multiple channel partners for delivery
- Potentially multiple manufacturing sites behind the scenes, but the purchasing “supplier” identity remains the labeler and the NDC
Does CATAPRES-TTS-1 have generic or authorized equivalents that change the supplier list?
Answer: Supplier diversity increases when generics or authorized equivalents enter. If the market still prices and sells primarily as branded CATAPRES-TTS-1, suppliers remain largely tied to the brand labeler.
How generics alter supplier dynamics
When generics are available:
- Procurement may shift to generic labeler(s) and alternate NDCs
- Contracting can create multiple eligible SKUs
- Substitution policies and interchangeability rules become relevant for purchasing decisions
Timeline: when supplier availability can change (launch, shortages, site transfers)
Answer: Supplier availability for CATAPRES-TTS-1 changes when:
- Lot allocation shifts due to manufacturing outages
- Packaging component constraints affect release schedules
- Site transfers occur after equipment upgrades or capacity rebalancing
- Regulatory actions alter approved manufacturing locations
These changes typically show up in distributor lead times and availability signals rather than in public “supplier” lists.
Key Takeaways
- Primary supplier identity for procurement: CATAPRES-TTS-1 is supplied under the US brand sponsor labeler (Bausch Health US, LLC) and distributed through standard pharmaceutical wholesaler channels.
- Procurement approach: Contracting and ordering should use NDC and labeler as the actionable supplier identifiers.
- What changes supplier coverage: Generics/authorized equivalents, manufacturing site changes, and component shortages can broaden the set of purchasable SKUs and labelers, but the branded supplier identity is typically singular.
FAQs
-
What is the NDC for CATAPRES-TTS-1 and how do I find the labeler?
Use the FDA NDC Directory to retrieve the current NDC entry for CATAPRES-TTS-1 and read the “Labeler” field.
-
Can hospitals substitute CATAPRES-TTS-1 with a clonidine transdermal generic?
Substitution depends on formulary policy, interchangeability status, and the specific NDC covered under contract.
-
Who do I contact for CATAPRES-TTS-1 supply issues: the wholesaler or the labeler?
For channel-level fulfillment delays, start with the contracted wholesaler. For product-level issues, the labeler is the regulatory and commercial point of accountability.
-
How do manufacturing site changes show up for CATAPRES-TTS-1 procurement?
Lead times, lot availability, and NDC/label changes may occur; the most actionable signals are distributor allocation status and lot-level availability.
-
Do transdermal component supply constraints affect CATAPRES-TTS-1 availability?
Yes. Adhesive layer components, laminates, and packaging materials can impact lot release and distribution schedules.
References
- U.S. FDA. NDC Directory. https://www.accessdata.fda.gov/scripts/cder/ndc/
- U.S. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data
